Poland· PL-100535353
Aumseqa
A aumolertinib product containing aumolertinib, registered in Poland by SFL Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Aumolertinib is registered in 8 of 19 countries.
Countries holding a registration under ATC L01EB11 (aumolertinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Aumolertinib · ATC L01EB11
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Aumolertinib
- Manufacturer
- SFL Pharmaceuticals Deutschland GmbH
- Country
- Poland (PL)
- ATC code
- L01EB11
- ATC class
- Aumolertinib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aumolertinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAumseqa 55 mgSfl Pharmaceuticals Deutschland
- CzechiaAUMSEQASFL Pharmaceuticals Deutschland GmbH, Lörrach
- FinlandAumseqaSFL Pharmaceuticals Deutschland GmbH
- IrelandAumseqa 55 mg film-coated tabletsSFL Pharmaceuticals Deutschland GmbH
- IcelandAumseqaSFL Pharmaceuticals Deutschland GmbH
- NetherlandsAumseqa 55 mg filmomhulde tabletSFL Pharmaceuticals Deutschland GmbH
- SwedenAumseqa 55 mg Filmdragerad tablettSFL Pharmaceuticals Deutschland GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9499a7d1-9a41-4533-ba1e-e11f3f905da4 GET /v1/drugs/9499a7d1-9a41-4533-ba1e-e11f3f905da4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "55 mg",
"packaging": "Rpz ¦ EU/1/25/2006/001 ¦ 166391\n1 butel. 60 tabl.",
"substance": "Aumolertinib 55 mg",
"common_name": "Aumolertinib",
"pl_product_id": "100535353",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about aumolertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.